Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.70 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.70 |
| ▸ | SLC25A1 | P53007 | 1/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | VCAM1 | P19320 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.52 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.52 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.52 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.51 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7572360 | 0.85 | KDM4E (0.59) | DNMT1DNMT3ARECQLKMT2AALDH1A1 | |
| SCHEMBL11749307 | 0.83 | SLC25A1 (0.68) | DNMT1DNMT3ASLC25A1VCAM1KMT2A | |
| SCHEMBL29928232 | 0.82 | DNMT1 (1.00) | DNMT1DNMT3ASLC25A1VCAM1KMT2A | |
| SCHEMBL31404890 | 0.82 | DNMT1 (0.67) | DNMT1DNMT3ASLC25A1VCAM1KMT2A | |
| SCHEMBL17927205 | 0.82 | DNMT1 (1.00) | DNMT1DNMT3ASLC25A1VCAM1KMT2A | |
| SCHEMBL2098718 | 0.80 | RECQL (0.55) | DNMT1DNMT3ARECQLKMT2AALDH1A1 | |
| SCHEMBL29918322 | 0.80 | SLC25A1 (1.00) | DNMT1DNMT3ASLC25A1RECQLVCAM1 | |
| SCHEMBL30000258 | 0.80 | SLC25A1 (1.00) | DNMT1DNMT3ASLC25A1RECQLVCAM1 | |
| SCHEMBL30777865 | 0.80 | SLC25A1 (1.00) | DNMT1DNMT3ASLC25A1RECQLVCAM1 | |
| SCHEMBL3611184 | 0.80 | ALDH1A1 (0.80) | DNMT1DNMT3ASLC25A1VCAM1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718650-B2 | Aryl sulfonamide compounds for treating obesity | BIOVITRUM AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-7566715-B2 | Substituted sulfonamide compounds useful for the prophylaxis and treatment of conditions relating to obesity, type II diabetes and/or disorders of the central nervous system | BIOVITRUM AB (SE) | 2009-07-28 | — | — | US | disclosed |
| US-20080096873-A1 | NEW COMPOUNDS | BIOVITRUM AB, A SWEDEN CORPORATION | 2008-04-24 | — | — | US | disclosed |
| US-7319097-B2 | Treatment of type II diabetes with benzenesulfonamide substituted with an N-heterocycle: N-[2-amino-5-(1,4-diazepan-1-yl)phenyl]benzenesulfonamide, N-[4-amino-5-(piperazinyl)phenyl]benzenesulfonamide, 3-amino-4-(5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-N-phenyl-benzenesulfonamide hydrochloride | BIOVITRUM AB (SE) | 2008-01-15 | — | — | US | disclosed |
| US-7173035-B2 | Arylsulfonamide compounds | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-20060009446-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2006-01-12 | — | — | US | disclosed |
| US-20050288275-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2005-12-29 | — | — | US | disclosed |
| US-6969710-B2 | Compounds | BIOVITRUM AB (SE) | 2005-11-29 | — | — | US | disclosed |
| EP-1406884-A1 | ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS | BIOVITRUM AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| US-20030149020-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-07 | — | — | US | disclosed |
| US-20030149019-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-07 | — | — | US | disclosed |
| WO-2002092585-A1 | NOVEL, ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS | BIOVITRUM AB (SE) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149020-A1 | New compounds | GPR119, SULT2A1, NAT1 | DNMT1 4144/4885DNMT3A 4655/4885SLC25A1 938/4885 |
| US-20030149019-A1 | New compounds | GPR119, SULT2A1, NAT1 | DNMT1 4144/4885DNMT3A 4655/4885SLC25A1 938/4885 |
| US-20060009446-A1 | New compounds | GPR119, SULT2A1, STS | DNMT1 4229/4885DNMT3A 4675/4885SLC25A1 937/4885 |
| US-20080096873-A1 | NEW COMPOUNDS | GPR119, SULT2A1, STS | DNMT1 4229/4885DNMT3A 4675/4885SLC25A1 937/4885 |
| US-20050288275-A1 | New compounds | GPR119, SULT2A1, STS | DNMT1 4229/4885DNMT3A 4675/4885SLC25A1 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.